

# Triovance Named Finalist in Prestigious INCIDE Booster Program

*Company to Showcase its Innovative 'Cure from Within' Diabetic Foot Care Technology to Participating INCIDE Investors as it Advances Toward Clinical Studies*

MEXICO CITY, MEXICO, September 25, 2024 /EINPresswire.com/ -- Triovance is proud to announce its selection as one of the finalists in the highly competitive INCIDE Booster Program, which aims to accelerate the development of innovative companies and academic institutions in the life sciences sector. Out of 67 applicants, Triovance is one of only eight private companies selected as a finalist.



Organized by Fundación Incide A.C., the INCIDE Booster Program is a groundbreaking initiative focused on driving competitiveness, productivity and value creation in science, technology and innovation companies originating in Latin America. The program spans eight weeks and offers finalists an intensive schedule of workshops, mentorship sessions and conferences, providing them with the knowledge and resources necessary to succeed in the biotechnology industry.

As part of INCIDE, participants present their refined business strategies to potential investors and industry leaders to secure investment and business partnerships.

"We're really pleased to be selected as a finalist in the INCIDE Booster Program, and we look forward to showcasing our 'cure from within' approach to treating diabetic foot disease with investors," said Blanca Segura, PhD, CEO of Triovance.

## About Triovance

Triovance is a late-preclinical stage biotechnology company transforming the treatment of diabetic foot disease by curing from within. Its lead product, TRV-01, is an engineered skin substitute, genetically modified to deliver insulin and VEGF directly to wound beds. TRV-01



We're really pleased to be selected as a finalist in the INCIDE Booster Program, and we look forward to showcasing our 'cure from within' approach to treating diabetic foot disease with investors"

*Blanca Segura, PhD, CEO of  
Triovance.*

enhances blood flow and improves cellular regeneration while protecting the wound. A low-cost, non-invasive, scalable solution for outpatient care, it is the only therapeutic solution that cures diabetic foot disease at the source. Visit [www.triovance.com](http://www.triovance.com) or follow us on LinkedIn.

#### About the INCIDE Booster Program

The INCIDE Pharma & Healthtech Booster by New Genesis is an intensive eight-week program for biotechnology startups, providing tools and insights to raise capital successfully. Through workshops and one-on-one mentoring sessions, participants receive guidance from the New Genesis team and pharmaceutical industry leaders on

their business model, intellectual property strategy, market assessment and investor pitch materials. At the end of the program, finalists present their pitch in a Demo Day to secure investments and partnerships from pharmaceutical companies, venture capital firms and family offices.

Katie Morris, Ph.D.

ENTENTE Network

[katiemorris@ententeinc.com](mailto:katiemorris@ententeinc.com)

Visit us on social media:

[LinkedIn](#)

---

This press release can be viewed online at: <https://www.einpresswire.com/article/746289121>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2024 Newsmatics Inc. All Right Reserved.